Search results for "Systemic Sclerosis"

showing 10 items of 33 documents

Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and De…

2016

Objective.Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might modulate this molecule.Methods.After ethical approval, mesenchymal stem cells (MSC) and fibroblasts …

0301 basic medicineAdultMalePathologymedicine.medical_specialtyImmunologyADAM12 Protein03 medical and health sciencesYoung AdultRheumatologyFibrosisTransforming Growth Factor betamedicineImmunology and AllergyHumansProgenitor cellMyofibroblastsSkinintegumentary systembusiness.industryMedicine (all)FIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Rheumatology; Immunology; Immunology and AllergyMesenchymal stem cellTransdifferentiationMesenchymal Stem CellsMiddle Agedmedicine.diseaseFibrosisActinsUp-RegulationSettore MED/16 - Reumatologia030104 developmental biologymedicine.anatomical_structurePERICYTEFIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Immunology and Allergy; Rheumatology; Immunology; Medicine (all)SYSTEMIC SCLEROSISCell TransdifferentiationScleroderma DiffuseFemalePericyteBone marrowbusinessPericytesMyofibroblastTransforming growth factorThe Journal of rheumatology
researchProduct

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patient…

2017

Background The use of stem cells, including mesenchymal stem cells (MSCs), for regenerative medicine is gaining interest for the clinical benefits so far obtained in patients. This study investigates the use of adipose autologous tissue in combination with platelet-rich plasma (PRP) to improve the clinical outcome of patients affected by systemic sclerosis (SSc). Methods Adipose-derived mesenchymal stem cells (AD-MSCs) and PRPs were purified from healthy donors and SSc patients. The multilineage differentiation potential of AD-MSCs and their genotypic–phenotypic features were investigated. A cytokine production profile was evaluated on AD-MSCs and PRPs from both healthy subjects and SSc pat…

0301 basic medicineMalePathologyCell- and Tissue-Based TherapyAdipose tissueMedicine (miscellaneous)Gene ExpressionRegenerative MedicineCell therapyCell therapySystemic sclerosiAdipose-derived mesenchymal stem cells; Cell therapy; Lipofilling; Mesenchymal stem cells; Platelet-rich plasma; Regenerative medicine; Systemic sclerosis; Medicine (miscellaneous); Molecular Medicine; Biochemistry Genetics and Molecular Biology (miscellaneous); Cell Biologylcsh:QD415-436skin and connective tissue diseasesMesenchymal stem cellSkinAged 80 and overlcsh:R5-920integumentary systemCell DifferentiationStromal vascular fractionMiddle Agedmedicine.anatomical_structureAdipose TissueMolecular MedicineCytokinesSystemic sclerosisFemaleStem celllcsh:Medicine (General)Adultmedicine.medical_specialtyPrimary Cell CultureConnective tissueNeovascularization PhysiologicMesenchymal Stem Cell TransplantationBiochemistry Genetics and Molecular Biology (miscellaneous)lcsh:Biochemistry03 medical and health sciencesPlatelet-rich plasmaAntigens CDAdipose-derived mesenchymal stem cellsmedicineHumansCell ProliferationAdipose-derived mesenchymal stem cellLipofillingScleroderma Systemicbusiness.industryRegeneration (biology)ResearchMesenchymal stem cellMesenchymal Stem CellsCell Biology030104 developmental biologyPlatelet-rich plasmaImmunologybusinessStem cell researchtherapy
researchProduct

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibrobla…

2018

Abstract Background Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules modulating myofibroblast differentiation and proliferation, respectively. There is evidence linking CD248 with these two molecules, both highly expressed in patients with SSc, and suggesting that CD248 may be a therapeutic target for several diseases. The aim of this work was to evaluate the expression of CD248 in SSc skin and its ability to modulate SSc fibrotic process. Methods After ethical approval was obtained, skin biopsies were co…

0301 basic medicineMalelcsh:Diseases of the musculoskeletal systemProton Pump InhibitorFibrosiCellular differentiationmedicine.medical_treatmentSystemic sclerosiFibrosisImmunology and AllergyMedicineMyofibroblastsskin and connective tissue diseasesCells CulturedSkinintegumentary systemCell DifferentiationMiddle AgedMesenchymal Stem CellBenzamidesSystemic sclerosisFemaleMyofibroblastResearch ArticleHumanAdultStromal cellImmunology03 medical and health sciencesYoung AdultRheumatologyBenzamideAntigens CDAntigens NeoplasmHumansGene silencingCell ProliferationMyofibroblastScleroderma Systemicbusiness.industryGrowth factorMesenchymal stem cellStromal CellMesenchymal Stem CellsProton Pump Inhibitorsmedicine.diseaseFibrosisCD248Settore MED/16 - Reumatologia030104 developmental biologyCancer researchStromal Cellslcsh:RC925-935CD248; Fibrosis; Systemic sclerosis; Rheumatology; Immunology and Allergy; ImmunologybusinessTransforming growth factor
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

Association between hypovitaminosis D and systemic sclerosis: True or fake?

2016

Abstract Background Vitamin D insufficiency/deficiency is considered a major factor triggering and enhancing several autoimmune disorders; hypovitaminosis D has been reported to be common in Systemic Sclerosis (SSc). Previous studies assessing vitamin D insufficiency/deficiency in SSc have been reviewed, and the relation with pathogenesis and clinical features has been examined. Content Eligibility criteria were: reporting measurement of Vitamin D serum levels in all participants and evaluating adult onset-SSc individuals as patients group. Results: The association between clinical features and low hormone levels is controversial. Manifold data have shown vitamin D insufficiency/deficiency …

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryVitamin D Systemic Sclerosis Hypovitaminosis D AutoimmunityDiseasemedicine.disease_causeBiochemistryCalcitriol receptorAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicineHypovitaminosisDLCOInternal medicinemedicineVitamin D and neurologyHumansVitamin D030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBiochemistry (medical)General MedicineVitamin D Deficiency030104 developmental biologyImmunologybusinessHormone
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

Interleukin-9 and T helper type 9 cells in rheumatic diseases

2016

Summary Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide belonging to the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private receptor IL-9R and the IL-2 receptor, gamma (IL-2RG), a common gamma subunit shared by the receptors of many different cytokines. The IL-9R is expressed widely and IL-9 impacts a number of effector cells, such as effector T cells, B cells, innate lymphoid cells, mast cells, polymorphonuclear cells, epithelial cells and smooth muscle cells, playing an important role in regulating inflammatory immunity. The critical role of IL-9 in promoting cellular and humoral immune responses makes it an important focus of pot…

0301 basic medicinerheumatoid arthritispsoriatic arthritisystemic sclerosisSLEReview ArticleIL-9; psoriatic arthritis; rheumatoid arthritis; SLE; systemic sclerosis; Th9 cells; vasculitis; Immunology and Allergy; ImmunologyTh9 cellsvasculitisArthritis RheumatoidInterleukin 210302 clinical medicineT-Lymphocyte SubsetsTh9 cellIL-9; SLE; Th9 cells; psoriatic arthritis; rheumatoid arthritis; systemic sclerosis; vasculitisLupus Erythematosus SystemicMedicineImmunology and AllergyIL-2 receptorpsoriatic arthritisB-LymphocytesInterleukin-17Innate lymphoid cellT-Lymphocytes Helper-InducerAcquired immune systemInterleukin 10vasculitiInterleukin 12systemic sclerosiSignal TransductionImmunologyAutoimmune Diseases03 medical and health sciencesRheumatic DiseasesAnimalsHumans030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryArthritis PsoriaticInterleukin-9rheumatoid arthritiIL-9Immunity HumoralInterleukin 33Settore MED/16 - Reumatologia030104 developmental biologyCTLA-4Immunologybusiness
researchProduct

Immunosuppressive treatment for systemic sclerosis—Therapeutic challenges during the COVID ‐19 pandemic

2020

2019-20 coronavirus outbreakmedicine.medical_specialtyLetterCoronavirus disease 2019 (COVID-19)systemic sclerosisPneumonia ViralDermatologySclerodermaCOVID‐19Risk FactorsPsoriasisPandemicmedicineHumansPsoriasisLettersIntensive care medicinePandemicsImmunosuppressive treatmentbusiness.industryCOVID-19immunosuppressive treatmentGeneral Medicinemedicine.diseasePneumoniaCoronavirus InfectionsbusinessImmunosuppressive AgentsCoronavirus InfectionsDermatologic Therapy
researchProduct

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling

2019

AbstractSystemic Sclerosis (SSc) is a disease with limited therapeutic possibilities. Mesenchymal stem cells (MSCs)-therapy could be a promising therapeutic option, however the ideal MSCs source has not yet been found. To address this problem, we perform comparison between bone marrow (BM)-MSCs and adipose (A)-MSCs, by the miRs expression profile, to identify the gene modulation in these two MSCs source. MicroRNAs (miRs) are RNAs sequences, regulating gene expression and MSCs, derived from different tissues, may differently respond to the SSc microenvironment. The miRs array was used for the miRs profiling and by DIANA-mirPath tool we identified the biological functions of the dysregulated …

Adult0301 basic medicineTherapeutic gene modulationAutoimmune diseasesCellular differentiationGene regulatory networklcsh:MedicineBone Marrow CellsBiologyRegenerative medicineArticle03 medical and health sciences0302 clinical medicinemicroRNAmedicineHumansGene Regulatory Networkslcsh:ScienceCells CulturedSystemic SclerosiCell ProliferationRegulation of gene expressionScleroderma SystemicMultidisciplinarySequence Analysis RNAGene Expression ProfilingMesenchymal stem celllcsh:RCell DifferentiationMesenchymal Stem CellsSettore MED/16 - ReumatologiaMicroRNAs030104 developmental biologymedicine.anatomical_structureAdipose TissueGene Expression RegulationCancer researchSystemic sclerosisFemalelcsh:QBone marrow030217 neurology & neurosurgeryScientific Reports
researchProduct